Intellia Therapeutics (NTLA) Statistics

Intellia Therapeutics Inc (NTLA) is a biotechnology company that focuses on developing and commercializing gene editing technologies. The company's main platform is CRISPR/Cas9, a revolutionary gene editing tool that allows scientists to modify genes with unprecedented precision. With this technology, Intellia aims to develop novel therapies for a wide range of diseases, including genetic disorders, cancer, and infectious diseases. As of the latest statistics, NTLA has a market capitalization of $4.5 billion and a current share price of $130. The stock has a 52-week high of $155 and a 52-week low of $56.

When it comes to valuation metrics, NTLA has a forward price-to-earnings (P/E) ratio of 80. This indicates that investors expect strong future earnings growth from the company. NTLA also has a price-to-sales (P/S) ratio of 73, suggesting that the stock is trading at a premium compared to its revenue. In terms of fundamentals, NTLA has a positive earnings per share (EPS) of $1.50 and a return on equity (ROE) of 13%. These numbers reflect the company's ability to generate profits and provide a return to its shareholders.